Pharmacoeconomic Analysis of Micafungin (Mycamine) 100 mg and 150 mg Daily In the Treatment of Candidemia.
نویسندگان
چکیده
We conducted a retrospective study to assess pharmacoeconomic outcomes of patients who received a daily dose of micafungin 100 mg or 150 mg to treat candidemia. The once-daily 100-mg dose resulted in clinical and mycological outcomes similar to those achieved with 150 mg daily and succeeded in reducing drug-acquisition costs for treating hospitalized patients with candidemia.
منابع مشابه
Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis.
BACKGROUND Invasive candidiasis is an important cause of morbidity and mortality among patients with health care-associated infection. The echinocandins have potent fungicidal activity against most Candida species, but there are few data comparing the safety and efficacy of echinocandins in the treatment of invasive candidiasis. METHODS This was an international, randomized, double-blind tria...
متن کاملPharmacokinetics of Micafungin in Adult Patients with Invasive Candidiasis and Candidemia
Micafungin is an efficacious and well-tolerated echinocandin with in vitro and in vivo activity against a broad range of Candida species. The objective of this randomized, double-blind study was to examine the pharmacokinetic parameters of micafungin and its metabolites in a subset of adult patients with invasive candidiasis or candidemia. The study was conducted at 27 sites in four countries, ...
متن کاملOnce-weekly micafungin therapy is as effective as daily therapy for disseminated candidiasis in mice with persistent neutropenia.
The effect of micafungin dose scheduling on the treatment of candidemia is unknown. Neutropenic mice with disseminated Candida glabrata infection were treated with single intraperitoneal micafungin doses of 0 to 100 mg/kg of body weight and sacrificed 7 days later. The maximal decline in kidney fungal burden was 5.8 log(10) CFU/g. A 1-week pharmacokinetic-pharmacodynamic study revealed a micafu...
متن کاملCost-effectiveness of micafungin as an alternative to fluconazole empiric treatment of suspected ICU-acquired candidemia among patients with sepsis: a model simulation
INTRODUCTION Recent epidemiologic literature indicates that candidal species resistant to azoles are becoming more prevalent in the face of increasing incidence of hospitalizations with candidemia. Echinocandins, a new class of antifungal agents, are effective against resistant candidal species. As delaying appropriate antifungal coverage leads to increased mortality, we evaluated the cost-effe...
متن کاملTreatment of candidemia and invasive candidiasis in the intensive care unit: post hoc analysis of a randomized, controlled trial comparing micafungin and liposomal amphotericin B
INTRODUCTION Invasive candidiasis and candidemia are life-threatening nosocomial infections in intensive care patients. METHODS A post hoc analysis of a phase 3 trial assessing micafungin (100 mg/day for subjects > 40 kg; 2 mg/kg/day for subjects <or= 40 kg) versus liposomal amphotericin B (3 mg/kg/day). Subgroups were defined according to the type of ward on the first day of treatment: inten...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- P & T : a peer-reviewed journal for formulary management
دوره 34 4 شماره
صفحات -
تاریخ انتشار 2009